In all critical stages in the drug life cycle, BaiPharm can provide specific
recommendations and actionable solutions to clients.
WEBINARS
MORE >
OTC Drug Focus: How to Start and Manage Your Cross-border E-commerce (CBEC) Operations in China
[ Thursday ,3rd November 2022 ]
LATEST NEWS
INDUSTRY
Marketing Approval
Priority Review and Approval
Innovative Drug
Generic Drug
Biological Product
Cancer
Drug Registration
New Drug
COVID-19
Monthly Report: New Drug Approvals in China | January 2023
In January 2023, China NMPA approved 15 new drugs, including 8 chemical drugs and 7 biological products. Simcere's Simnotrelvir Tablets / Ritonavir Tablets and Shanghai Vinnerna Biosciences' Deuremidevir Hydrobromide got conditional approvals for COVID-19 treatment.
Feb 03, 2023
POLICY
China Adds 111 Drugs to 2022 National Reimbursement Drug List
On Jan. 18, 2023, China issued the 2022 National Reimbursement Drug List (NRDL), a list of drugs fully or partially reimbursed by the national basic health insurance. After bidding or price negotiation between NHSA and pharma companies, 111 drugs entered the 2022 NRDL and 3 drugs were delisted. The average price cut reached 60.1%.
Jan 20, 2023
REGULATION
Law & Regulation
Pharmacovigilance
Marketing Approval
Volume-Based Procurement
Generic Drug
Drug Registration
E-commerce
2022 Recap: Top 10 BaiPharm Stories on China Pharmaceutical Regulations
ChemLinked BaiPharm Portal has been tracking and interpreting China’s pharmaceutical regulations during the year of 2022. Here are the top 10 stories we selected for you to grasp China’s regulatory dynamics.
Jan 13, 2023
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | December 2022
Check out China's pharmaceutical regulatory updates in December 2022: 1. China NMPA Adds OTC Status to a Former Prescription Drug; 2. China NMPA Releases the 62nd List of RLDs; 3. China NMPA Issues Regulation on Supervising MAH as the Main Responsible Entity for Drug Safety; 4. China NMPA Requires Licenses for Importing and Exporting Anesthetics and Psychoactive Drugs; 5. China CDE Specifies Requirements for Electronic Submission of Drug Applications...
Jan 09, 2023
POLICY
China Levies Zero Tariff on Active Pharmaceutical Ingredients of COVID-19, Cancer, and Rare Disease Drugs
According to China's 2023 Tariff Adjustment Plan, tariffs are provisionally lowered to zero for 22 categories of active pharmaceutical ingredients of medicines for treating COVID-19, cancer, and rare diseases.
Jan 05, 2023
